PitchBook：2024年分析师说明共生物测试版报告（英文版）

The promise of AI and digital biology dominated discussions at SynBioBeta 2024. • Biopharma remains a strong sector within SynBio, driving funding through high-impact investments and larger exits such as IPOs and M&A despite a postpandemic shift toward fewer, larger deals. • Industrial biotech has struggled with investment due to low exit activity and profitability, with a need for stronger data to de-risk the science. • AI and digital biology are focusing on generative AI reshaping inves